Desperate cancer patients get early access to promising drug combo
NCT ID NCT06751524
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tried standard treatments and have no other good options. A doctor must decide if the potential benefit outweighs the risks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Botensilimab and balstilimab (combination immunotherapy drugs given by IV infusion)
- What this could lead to
- If it works, this could provide a treatment option for people with advanced cancers who have run out of standard therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence is limited. The drugs are still investigational and may not work for everyone; side effects from immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can new drug cocktails reawaken the immune system against melanoma?
- A second look: MRI screening may spot hidden prostate cancers
- Could a vaccine help fight Hard-to-Treat cancers?